

**2017 ASH Annual Meeting  
ASH LIVE Remote Viewing Sessions**

Channel	Sat 12/9 7:30 a.m. - 9:00 a.m.	Sat 12/9 9:30 a.m. - 11:00 a.m.	Sat 12/9 12:00 p.m. - 1:30 p.m.	Sat 12/9 12:30 p.m. - 1:30 p.m.	Sat 12/9 2:00 p.m. - 3:30 p.m.	Sat 12/9 4:00 p.m. - 5:30 p.m.	Sun 12/10 7:30 a.m. - 9:00 a.m.	Sun 12/10 9:30 a.m. - 11:00 a.m.	Sun 12/10 11:15 a.m. - 12:15 p.m.	Sun 12/10 12:00 p.m. - 1:30 p.m.	Sun 12/10 12:30 p.m. - 1:30 p.m.	Sun 12/10 1:30 p.m. - 2:00 p.m.
<b>1</b>	Next-Generation Sequencing in Routine Diagnostics: Are We There Yet?	Genetic Pathways That Disrupt Hematopoietic Stem Cell Function in Inherited Bone Marrow Failure	623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Mantle Cell Lymphoma, New Therapies	Ham-Wasserman Lecture	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Novel Agents and Upfront Approaches	Hematopoietic Stem Cell Generation: Reprogramming and Expansion	904. Outcomes Research—Malignant Conditions: Quality Of Life and Outcomes in Myelodysplastic Syndromes and Leukemias	Special Scientific Symposium on Targeted Therapy: What is the Best Target?	Featured Topic: Hemophilia Revolution			Announcement of Awards: ASH Mentor Awards, ASH Award for Leadership in Promoting Diversity, ASH Outstanding Service Award, ASH Public Service Award, and Wallace H. Coulter Award for Lifetime Achievement in Hematology
<b>2</b>	Special Education Session on New ASH Clinical Practice Guidelines on Venous Thromboembolism	Primary Immunodeficiencies From Childhood to Adulthood		703. Adoptive Immunotherapy: Immune Therapeutics for Hematologic Cancers: Artificial Receptors and Beyond	Genetic Pathways That Disrupt Hematopoietic Stem Cell Function in Inherited Bone Marrow Failure	Primary Immunodeficiencies From Childhood to Adulthood	632. Chronic Myeloid Leukemia: Therapy: Treatment Discontinuation, Dose Reduction, and Prognostic Indicators	627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Outcomes in Rare Entities: HTLV-1 ATLL, Gray Zone Lymphoma, Primary CNS Lymphoma, and Intravascular DLBCL	Quality Conversations on Social Media: Achieving Credibility and Efficiency Together			
<b>3</b>	621. Lymphoma—Genetic/Epigenetic Biology: Genomic characterization of lymphoma and beyond	625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: New Tools and Emerging Immune-Modulatory Approaches for Non-Hodgkin Lymphomas	506. Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion, and Stromal Stem Cells: Hematopoietic Microenvironment II		627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Predicting Efficacy and Safety of CAR-T cells and Checkpoint Blockade	641. CLL: Biology and Pathophysiology, excluding Therapy: Therapeutic Resistance in CLL	621. Lymphoma—Genetic/Epigenetic Biology: Molecular approaches to describe, monitor, and target lymphoma	731. Clinical Autologous Transplantation: Results: Novel Conditioning & Maintenance Approaches		627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Molecular Characterization of Diffuse Large B Cell Lymphoma		
<b>4</b>	Chronic Myeloid Leukemia: Where Are We in the Current TKI Era?	Clonal Evolution in Myeloid Malignancies	637. Myelodysplastic Syndromes—Clinical Studies: Predicting Drug Response Using Novel Genomic Algorithms		Advances in Cellular Immunotherapy for Lymphoid Malignancies	Special ASH Symposium on CAR-T	Individualizing Therapy in Chronic Lymphocytic Leukemia	Clonal Evolution in Myeloid Malignancies		637. Myelodysplastic Syndromes—Clinical Studies: Inflammation, Immunity, and Iron		
<b>5</b>	The Expanding Role of Immunotherapy in Non-Hodgkin Lymphoma	Novel Therapeutics in Myeloma	614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Therapy, Excluding CAR-T Cell		Controversies in Myeloma	Indolent Lymphoma: How Understanding Disease Biology Is Influencing Clinical Decision-Making	Hodgkin Lymphoma: New Insights and New Approaches	The Expanding Role of Immunotherapy in Non-Hodgkin Lymphoma		623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Follicular Lymphoma, First Line		
<b>6</b>	Acute Myeloid Leukemia: How Can We Improve Upon “Standard” Therapy?	Advances in Cellular Immunotherapy for Lymphoid Malignancies	615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Innovative AML Treatment with Approved Agents		Evolving Approaches to Gene Therapy for Blood Diseases	New Approaches to Understanding Microbial Immune System Interactions	Dilemmas in Pediatric Hematologic Malignancy	Novel Epigenetic Modifications in Cancer and Development		642. CLL: Therapy, excluding Transplantation: Targeting MRD Negative CLL Through Combinations of Novel Agents and Antibody		
<b>7</b>	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Prognostic and predictive markers	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Prognostic information and therapeutic implication			Special Symposium on Quality	602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Disordered epigenetic regulation in acute myeloid leukemia	617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Promoting leukemogenesis and risk factors	New Innovations in Platelet Regulation of Tumor Growth and Metastasis		623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Indolent Lymphomas, Novel Therapies, and Diagnostics		
<b>8</b>	636. Myelodysplastic Syndromes—Basic and Translational Studies: Immune and niche dysfunction in MDS	636. Myelodysplastic Syndromes—Basic and Translational Studies: Molecular Mechanisms of MDS			634. Myeloproliferative Syndromes: Clinical: Biologic-Clinical Correlative Studies in MPNs, Including Transplant	634. Myeloproliferative Syndromes: Clinical: Phase I/II Trials of Novel Agents in MPNs	634. Myeloproliferative Syndromes: Clinical: Phase III and Long-Term Outcome Studies in MPNs	635. Myeloproliferative Syndromes: Basic Science: Identification of novel targets for the treatment of myeloproliferative neoplasms		653. Myeloma: Therapy, excluding Transplantation: Upfront Therapy for Multiple Myeloma: Induction and Maintenance		

**2017 ASH Annual Meeting  
ASH LIVE Remote Viewing Sessions**

<b>Channel</b>	<b>Sat 12/9 7:30 a.m. - 9:00 a.m.</b>	<b>Sat 12/9 9:30 a.m. - 11:00 a.m.</b>	<b>Sat 12/9 12:00 p.m. - 1:30 p.m.</b>	<b>Sat 12/9 12:30 p.m. - 1:30 p.m.</b>	<b>Sat 12/9 2:00 p.m. - 3:30 p.m.</b>	<b>Sat 12/9 4:00 p.m. - 5:30 p.m.</b>	<b>Sun 12/10 7:30 a.m. - 9:00 a.m.</b>	<b>Sun 12/10 9:30 a.m. - 11:00 a.m.</b>	<b>Sun 12/10 11:15 a.m. - 12:15 p.m.</b>	<b>Sun 12/10 12:00 p.m. - 1:30 p.m.</b>	<b>Sun 12/10 12:30 p.m. - 1:30 p.m.</b>	<b>Sun 12/10 1:30 p.m. - 2:00 p.m.</b>
<b>9</b>	The Yin and Yang of Myeloma: Understanding and Harnessing Normal Plasma Cell Biology to Better Treat Myeloma	612. Acute Lymphoblastic Leukemia: Clinical Studies: Advances in the Treatment of ALL			Iron Trafficking: Ins and Outs in Organelles, Organs, and Organisms	723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: New strategies in diagnosis and therapy of malignancy relapse	723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Progress in survivorship care of transplant patients	618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Biology, Signaling Mechanisms, and Response in ALL			ASH-EHA Joint Symposium	
<b>10</b>	618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Genetic and Metabolomic Profiling in ALL	Special Scientific Symposium on Hot Topics in Hematology: New Pathways Linking Hematopoiesis, Thrombosis, and Cardiovascular Disease			Special Scientific Symposium on Understanding and Modulating the DNA Damage Response	AML MATTERS: A Multidisciplinary Approach To Testing and Diagnosis, Evaluation of Risk, and Personalized Treatment Selection	New Approaches to Understanding Microbial Immune System Interactions	Next-Generation Sequencing in Routine Diagnostics: Are We There Yet?				
<b>11</b>	Evolving Strategies in Aggressive B-Cell Lymphoma	Management of Sickle Cell Disease: Present and Future			Acute Lymphocytic Leukemia: New Approaches in Management	Novel Epigenetic Modifications in Cancer and Development	Hematopoietic Stem Cell Generation: Reprogramming and Expansion	Targeting T-Cell Exhaustion				
<b>12</b>	651. Myeloma: Biology and Pathophysiology, excluding Therapy: Transcriptional Regulatory Circuitries of Multiple Myeloma	Targeting T-Cell Exhaustion			Myelodysplastic Syndromes: Understanding the Current Treatment Landscape	The Yin and Yang of Myeloma: Understanding and Harnessing Normal Plasma Cell Biology to Better Treat Myeloma	Therapeutic Apheresis as an Immunomodulatory Tool	Indolent Lymphoma: How Understanding Disease Biology is Influencing Clinical Decision-Making				

2017 ASH Annual Meeting  
ASH LIVE Remote Viewing Sessions

Channel	Sun 12/10 2:00 p.m. - 4:00 p.m.	Sun 12/10 4:30 p.m. - 6:00 p.m.	Mon 12/11 7:00 a.m. - 8:30 a.m.	Mon 12/11 9:00 a.m. - 10:00 a.m.	Mon 12/11 10:30 a.m. - 12:00 p.m.	Mon 12/11 12:15 p.m. - 1:15 p.m.	Mon 12/11 1:30 p.m. - 2:30 p.m.	Mon 12/11 2:45 p.m. - 4:15 p.m.	Mon 12/11 4:30 p.m. - 6:00 p.m.	Mon 12/11 6:15 p.m. - 7:45 p.m.	Tue 12/12
1	Plenary Scientific Session	Beyond Sequencing: Emerging Tools for Analysis of Multi-Omic Genomic Data in Acquired and Inherited Hematologic Disease	626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Immune-Based Therapeutic Approaches	E. Donnal Thomas Lecture and Prize	624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Hodgkin Lymphoma Immunotherapy Studies; nodular lymphocyte predominant Hodgkin lymphoma clinical studies	Global Hematology Symposium		624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Hodgkin Lymphoma—Chemotherapy and PET Studies	624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: T-Cell Lymphoma Clinical Studies	508. Bone Marrow Failure: Inherited Bone Marrow Failure: Ribosomopathies and Related Disorders	9:30 a.m. - 9:45 a.m. Announcement of Awards: William Dameshek Prize and Henry M. Stratton Medal
2		Blood and Beyond: The Art of Perception	Emerging Issues in Clinical Care in Thalassemia		622. Lymphoma Biology—Non-Genetic Studies: Novel Mechanisms Implicated in Lymphoma Biology	Featured Topic: Combination Therapies: How Are We Deciding What to Utilize?		622. Lymphoma Biology—Non-Genetic Studies: Prognostic Biomarkers and Immune Mechanisms in Lymphoma	603. Oncogenes and Tumor Suppressors: Epigenetic and Post-Transcriptional Control	904. Outcomes Research—Malignant Conditions: Survivorship and Quality of Life in Lymphoid Malignancies	9:45 a.m. - 11:15 a.m. Presidential Symposium
3		801. Gene Therapy and Transfer: Immune Disorders, CAR-T Cells, and B-hemoglobinopathies	801. Gene Therapy and Transfer: Gene Therapy for Hemophilia and Improving Lentiviral Vectors		203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, Including HIV and Other Infections: B cells and Innate Immunity	ASH Choosing Wisely® Campaign: 2017 ASH Choosing Wisely Champions		203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: T cell biology and therapies	602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Disordered gene expression in myeloid and lymphoid leukemia	721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Preparative Regimens	11:15 a.m. - 11:30 a.m. Business Meeting
4		201. Granulocytes, Monocytes, and Macrophages I	201. Granulocytes, Monocytes, and Macrophages: SCN		Acute Lymphocytic Leukemia: New Approaches in Management		Ernest Beutler Lecture and Prize	653. Myeloma: Therapy, excluding Transplantation I	653. Myeloma: Therapy, excluding Transplantation: Studies in Relapsed and Refractory Multiple Myeloma	616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Therapies for Elderly Patients with AML	11:30 a.m. - 1:00 p.m. Best of ASH
5		623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Follicular Lymphoma, First Line	Dilemmas in Pediatric Hematologic Malignancy		Hodgkin Lymphoma: New Insights and New Approaches			Novel Therapeutics in Myeloma	ASH-FDA Joint Symposium on New Drug Approvals in Acute Myeloid Leukemia	603. Oncogenes and Tumor Suppressors: Nuclear Export and Metabolic Regulation	7:30 a.m. - 9:00 a.m. Late-Breaking Abstracts Session
6		ASH-FDA Joint Symposium on New Drug Approvals in Acute Lymphoid Leukemia and Non-Hodgkin Lymphoma	Individualizing Therapy in Chronic Lymphocytic Leukemia		Controversies in Myeloma			Evolving Strategies in Aggressive B-Cell Lymphoma	614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: CAR-T Cell Immunotherapy	653. Myeloma: Therapy, excluding Transplantation II	
7		653. Myeloma: Therapy, excluding Transplantation: Immunotherapy in Myeloma and Amyloid	Acute Myeloid Leukemia: How Can We Improve Upon "Standard" Therapy?		721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Alternative Donor Transplants			721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Microbiota, CMV, and GVHD	732. Clinical Allogeneic Transplantation: Results: Donor Selection in the Haplo Transplant Era	632. Chronic Myeloid Leukemia: Therapy: Results of Clinical Trials	
8		617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis I	602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Disordered epigenetic regulation in myeloid and lymphoid leukemia		904. Outcomes Research—Malignant Burden in Myeloma and Other Hematologic Malignancies			401. Basic Science and Clinical Practice in Blood Transfusion: Clinical and translational studies in transfusion medicine	401. Basic Science and Clinical Practice in Blood Transfusion: Dissecting pathophysiology in transfusion medicine using mouse models	612. Acute Lymphoblastic Leukemia: Clinical Studies: Immune-based therapies and rare subgroups	

2017 ASH Annual Meeting  
ASH LIVE Remote Viewing Sessions

Channel	Sun 12/10 2:00 p.m. - 4:00 p.m.	Sun 12/10 4:30 p.m. - 6:00 p.m.	Mon 12/11 7:00 a.m. - 8:30 a.m.	Mon 12/11 9:00 a.m. - 10:00 a.m.	Mon 12/11 10:30 a.m. - 12:00 p.m.	Mon 12/11 12:15 p.m. - 1:15 p.m.	Mon 12/11 1:30 p.m. - 2:30 p.m.	Mon 12/11 2:45 p.m. - 4:15 p.m.	Mon 12/11 4:30 p.m. - 6:00 p.m.	Mon 12/11 6:15 p.m. - 7:45 p.m.	Tue 12/12
9		635. Myeloproliferative Syndromes: Basic Science: Molecular events occurring within the myeloproliferative neoplasms	637. Myelodysplastic Syndromes—Clinical Studies: Genes Inform Genes, Morphology, and Clinical Outcomes		901. Health Services Research—Non-Malignant Conditions: Consultative Hematology			903. Outcomes Research—Non-Malignant Conditions: Health Impact and Mortality	903. Outcomes Research—Non-Malignant Conditions: Sickle Cell Disease		
10		732. Clinical Allogeneic Transplantation: Results: GVH and GVL	613. Acute Myeloid Leukemia: Clinical Studies: Risk Factors and Response-Adapted Personalized Medicine		The Challenge of Primary and Secondary Central Nervous System Lymphoma			When Graft Versus Tumor Fails: The Biology and Treatment of Relapse After Allogeneic Stem Cell Transplantation	627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies; PET-Guided Therapy and Prognostic Models in Diffuse Large B-Cell Lymphoma		
11		Myeloproliferative Neoplasms: New Insights in the Current Treatment Paradigm	Therapeutic Apheresis as an Immunomodulatory Tool		613. Acute Myeloid Leukemia: Clinical Studies: Novel Therapies for AML and APL			616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Emerging Molecularly-Targeted Therapies in AML	616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel Targeted and Immune-based Approaches in the Treatment of AML		
12		613. Acute Myeloid Leukemia: Clinical Studies: Advances in Frontline Therapy: Induction, Consolidation, and Maintenance	When Graft Versus Tumor Fails: The Biology and Treatment of Relapse After Allogeneic Stem Cell Transplantation		Myelodysplastic Syndromes: Understanding the Current Treatment Landscape			Myeloproliferative Neoplasms: New Insights in the Current Treatment Paradigm	642. CLL: Therapy, excluding Transplantation: New Agents, Infections, and PET/CT		